9 News & Press Releases found

Exscientia news

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

Collaborative efforts aim to accelerate drug discovery and improve clinical success

Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection

Research will be focused on up to 15 novel small molecule candidates across oncology and immunology

Exscientia will receive an upfront cash payment of $100 million with the potential of $5.2 billion in total milestones plus tiered r

Jan. 6, 2022

Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes

Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers

54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared to previous therapy

40% of patients experienced exceptional responses lasting at least three times longer than expected for their respective disease

VIENN

Oct. 11, 2021

Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering with Full Exercise of Underwriters’ Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public offering in the United States of 15,927,500 American Depositary Shares (“ADSs”) representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the full exerc

Oct. 4, 2021

Exscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million Concurrent Private Placements

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the pricing of its upsized initial public offering in the United States of 13,850,000American Depositary Shares (“ADSs”) representing 13,850,000 ordinary shares at an initial public offering price of $22.00 per ADS, for total gross proceeds

Sep. 29, 2021

Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential

Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches --
Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready assets; Gates Foundation to contribute sector expertise in antivirals and global public health --
Investment accelerates Exscientia’s Mpro coronavirus

Sep. 8, 2021